


Granted IN201811045804

# Drug delivery system having hsa-dope conjugate micelle



## NEED

The challenge lies in the limited solubility and loading capacity of curcumin, hindering its therapeutic efficacy and increasing production costs.

## SOLUTION

The invention introduces a drug delivery system encapsulating curcumin within a human serum albumin (HSA) and 1,2-Dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE) conjugate micelle.

## INNOVATION

The method involves developing a novel drug delivery system comprising HSA-DOPE conjugate micelle encapsulating a lipophilic drug for improved therapeutic outcomes in treating diseases like breast cancer.

## MARKET ANALYSIS

Market: Pharmaceutical and biotechnology industries

CAGR: estimated to be around 6-7%.

Potential Indian Clients: Pharmaceutical companies specializing in oncology treatments, research institutions focusing on cancer therapy, hospitals and clinics offering cancer treatment services

## WHY INVEST?

Drug delivery system

Cancer treatment

Human serum albumin (HSA)

1,2-Dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE)



## AT A GLANCE

- Current TRL NA
- Funded by NA
- IPC A61K, C07K
- Domain  
Drug delivery system for cancer treatment

For more information, reach out to (contact person), (designation), (organization) at (email ID) and (phone number)



Prof. Biswas Swati, Prof. Balram Ghosh, Ms. Kumari Preeti, Ms. Bobde Yamini

Department of, Pharmacy  
BITS Pilani, Hyderabad Campus

